AstraZeneca earmarks $200M to support its burgeoning biologics pipeline

Damian Garde

Thanks in part to its all-hands approach to immuno-oncology, 's is now nearly 50% , leading the company to lay out $ 200 million to build the capacity it will need to follow through on those in-development projects.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS